E2 ModeratePreliminaryPEM ?ObservationalPeer-reviewedMachine draft
Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An Interim Report.
Stein, Elisa, Heindrich, Cornelia, Wittke, Kirsten et al. · Journal of clinical medicine · 2023 · DOI
Quick Summary
This study tested a blood-cleaning procedure called immunoadsorption in 10 patients with ME/CFS that developed after COVID-19. The treatment removes harmful antibodies from the blood that may be attacking the body's nerve receptors. Seven patients showed meaningful improvement in physical function within four weeks, suggesting this approach may help some people with post-COVID ME/CFS.
Why It Matters
Post-COVID ME/CFS affects millions of people worldwide with limited treatment options. This study provides preliminary evidence that autoimmune mechanisms involving specific antibodies may contribute to symptoms in some patients, and that immunoadsorption—a relatively established medical technology—could offer benefit. These interim results support pursuing more rigorous controlled trials to test whether this approach could help post-COVID ME/CFS patients.
Observed Findings
- Seven of ten patients (70%) met responder criteria with SF36-PF improvements of 10–35 points at week four post-immunoadsorption
- All enrolled patients had post-COVID ME/CFS with elevated ß2-adrenergic receptor autoantibodies
- Functional improvement was the primary measured outcome at four weeks following treatment
Inferred Conclusions
- Immunoadsorption may improve physical function in a subset of post-COVID ME/CFS patients with ß2-adrenergic receptor autoantibodies
- Autoimmune mechanisms involving specific antibodies may contribute to post-COVID ME/CFS pathology
- These interim results justify progression to randomized controlled trials with sham apheresis controls and combination B-cell depletion therapy
Remaining Questions
- Which patient characteristics predict responder status to immunoadsorption?
- Do improvements persist beyond four weeks, and what is the durability of treatment effects?
- How does immunoadsorption compare to sham treatment in a blinded, controlled trial?
- Would combining immunoadsorption with B-cell depletion therapy produce greater or more durable improvements?
What This Study Does Not Prove
This small observational study without a control group cannot prove that immunoadsorption causes improvement—some patients may have improved naturally over time or due to placebo effects. It does not establish which patients are most likely to benefit, optimal treatment protocols, or whether benefits persist long-term. The findings cannot be generalized to all ME/CFS patients or those without the specific antibodies tested.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:No ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.3390/jcm12196428
- PMID
- 37835071
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026